Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension

Abstract

Supplemental Digital Content is available in the text Abstract Background: Riociguat is a novel soluble guanylate cyclase stimulator, and has been widely used for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (CTEPH). Some studies found that riociguat had better effects on CTEPH and proved to be safe, but the results were not utterly consistent. Therefore, the purpose of this study was to comprehensively evaluate the efficacy and safety of riociguat in the treatment of CTEPH. Methods: Randomized controlled trials on riociguat for the treatment of CTEPH were searched through such electronic databases as PubMed, Embase, Cochrane Library, Web of Science, China national knowledge internet, and Wanfang. The outcomes included exercise capacity, pulmonary hemodynamics, and side effects. The fixed-effects or random-effects models were used to analyze the pooled data, and heterogeneity was assessed by the I2 test. Results: Four studies involving 520 patients were included in this meta-analysis. Compared with the placebo group, riociguat significantly improved the hemodynamic indexes and increased 6-min walking distance (P\u200a<\u200a.0001, standardized mean difference (SMD)\u200a=\u200a−0.24, 95%CI −0.35 to −0.12; P\u200a<\u200a.00001, SMD\u200a=\u200a0.52, 95%CI 0.33 to 0.71), and decreased the Borg dyspnea score (P\u200a=\u200a.002, SMD\u200a=\u200a−0.31, 95%CI −0.51 to −0.12). In addition, riociguat could also significantly reduce the living with pulmonary hypertension scores and increase the EQ-5D scores (P\u200a=\u200a.01, SMD=−0.23, 95%CI −0.42 to −0.05; P\u200a<\u200a.00001, SMD\u200a=\u200a0.47, 95%CI 0.27 to 0.66), but there was no significant difference in the change level of N-terminal pro-hormone B-type natriuretic peptide in patients with riociguat (P\u200a=\u200a.20, SMD\u200a=\u200a−0.24, 95%CI −0.61 to −0.13). The common adverse events of riociguat were dyspepsia and peripheral edema, and no other serious adverse reactions were observed. Conclusions: We confirmed that riociguat had better therapeutic effects in improving the hemodynamic parameters and exercise capacity in patients with CTEPH without inducing serious adverse events. This will provide a reasonable medication regimen for the treatment of CTEPH.